MGI PHARMA Announces Change to Presentation Time at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Devices Conference
MGI Pharma zu myNews hinzufügen Was ist das?
MGI PHARMA, INC. (Nasdaq:MOGN) today announced that the time of
its presentation at the Merrill Lynch Global Pharmaceutical,
Biotechnology and Medical Devices Conference in London, England on
Thursday, September 20, 2007 has been changed to 5:00 a.m. ET. Bill
Spengler, Executive Vice President and Chief Financial Officer will
provide an overview of the Company, its products, pipeline and 2007
corporate goals.
The presentation will be webcast live and may be accessed by logging on
to MGI PHARMA’s corporate website at www.mgipharma.com.
Please connect to the Company’s website at
least 15 minutes prior to the live presentation to ensure adequate time
for any software download that may be necessary to listen to the
webcast. An archived version of the presentation will be available
through September 27, 2007.
About MGI PHARMA
MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and
acute care that acquires, researches, develops and commercializes
proprietary products that address the unmet needs of patients. MGI
PHARMA has a portfolio of proprietary pharmaceuticals, and intends to
become a leading biopharmaceutical company. MGI PHARMA markets Aloxi®
(palonosetron hydrochloride) Injection, Dacogen®
(decitabine) for Injection and Gliadel® Wafer
(polifeprosan 20 with carmustine implant) in the United States. The
Company directly markets its products in the U.S. and collaborates with
partners to reach international markets.
